Schematic illustration explaining the working principle of BCMA-CD19 bispecific CAR T cells used in current study. CD19 is the pan B cell marker but not expressed in long-lived plasma cells and BCMA ...

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third generation anti-CD19 ...

“CD19-directed chimeric antigen receptor (CAR)-modified T-cell therapy represents a new paradigm for the treatment of patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), however, ...

In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

Please provide your email address to receive an email when new articles are posted on . Most patients with B-cell lymphomas who relapsed after CAR T-cell therapy responded to the novel, ...

CD19-targeted CAR T-cell therapy shows a 65% response rate in Richter transformation, with median progression-free survival of 8 months and overall survival of 14.4 months. Early response and age are ...

STONY BROOK, N.Y.--(BUSINESS WIRE)--iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for autoimmune disorders and cancer, today announced the publication ...

Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025 Positive, early results ...